Erik Aerts, Zsolt Szabo, Matthias Hellberg-Naegele
2 February 2018
In the past two years proteasome inhibitors have risen in prominence reflecting the recent approval of two new agents, carfilzomib and ixazomib. This means there are three different agents of this class available for the treatment of multiple myeloma. These agents are highly effective and suitable for use in combination with other agents, however each has a different route of administration and an individual toxicity profile. Optimal patient management is required to use these agents to their full potential.
Read more (PDF) (185.6 KiB)